SEC Comment Letter for Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Aug 28, 2017
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Aug. 28, 2017 · CIK: 0001533040 · Accession: 0000000000-17-030256
AI Filing Summary & Sentiment
Reasoning
Letter
August 25, 2017 Dr. Geert Cauwenbergh President RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough, Massachusetts 01752 RXi Pharmaceuticals Corporation Registration Statement on Form S-1 Filed August 18, 2017 File No. 333-220062Re: Dear Dr. Cauwenbergh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Ryan A. Murr
Show Raw Text
August 25, 2017 Dr. Geert Cauwenbergh President RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough, Massachusetts 01752 RXi Pharmaceuticals Corporation Registration Statement on Form S-1 Filed August 18, 2017 File No. 333-220062Re: Dear Dr. Cauwenbergh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Ryan A. Murr